The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 19, 2020

Filed:

Feb. 23, 2017
Applicant:

Cornell University, Ithaca, NY (US);

Inventors:

Laurie H. Glimcher, New York, NY (US);

Xi Chen, Malden, MA (US);

Assignee:

Cornell University, Ithaca, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/7088 (2006.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 31/7088 (2013.01); A61K 45/06 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); C12Q 1/6886 (2013.01); C12Y 207/11001 (2013.01); G01N 33/5011 (2013.01); G01N 33/57415 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); G01N 2500/04 (2013.01); G01N 2800/52 (2013.01);
Abstract

Described herein is a previously unknown function of XBP1 in triple-negative breast cancer (TNBC). It is shown that XBP1 is preferentially spliced and activated in TNBC, and that deletion of XBP1 significantly blocks triple negative breast tumor growth. Strikingly, XBP1 is required for the self-renewal of breast tumor initiating cells (TICs). Genome-wide mapping of the XBP1 transcriptional regulatory network identified a fundamental role for XBP1 in regulating the response to hypoxia via the transcription factor hypoxia-inducible factor 1α (HIF1α). Importantly, activation of this pathway appears to carry prognostic implications, as expression of the XBP1-dependent signature is associated with shorter survival times in human TNBC.


Find Patent Forward Citations

Loading…